

## **BIBLIOGRAPHY**

- Adari, H., Lowy, D.R., Willumsen, B.M., Der, C.J. & McCormick, F. (1988). Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. *Science (New York, N.Y.)*. 240 (4851), pp. 518-521.
- Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N. & Perucho, M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes [online]. *Cell*. 53 (4), pp. 549-554.
- Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J., et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 26 (10), pp. 1626-1634.
- Avruch, J., Khokhlatchev, A., Kyriakis, J.M., Luo, Z., Tzivion, G., Vavvas, D. et al. (2001). Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. *Recent progress in hormone research*. 56, pp. 127-155.
- Bader, T. & Ismail, A. (2014). Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasis. *Alexandria Journal of Medicine*. 50 (3), pp. 203-209.
- Boelaert, K., Horacek, J., Holder, R.L., Watkinson, J.C., Sheppard, M.C. & Franklyn, J.A. (2006). Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. *The Journal of clinical endocrinology and metabolism*. 91 (11), pp. 4295-4301.
- Boichard, A., Croux, L., Al Ghuzlan, A., Broutin, S., Dupuy, C., Leboulleux, S., et al. (2012). Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. *The Journal of clinical endocrinology and metabolism*. 97 (10), pp. E2031-E2035.
- Burgess, J.R. (2002). Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982-1997). *Thyroid: official journal of the American Thyroid Association*. 12 (2), pp. 141-149.
- Castells, A., Puig, P., Mora, J., Boadas, J., Boix, L., Urgell, E., et al. (1999). K-ras mutations in DNA

- extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 17 (2), pp. 578-584.
- Chang, E.H., Gonda, M.A., Ellis, R.W., Scolnick, E.M. & Lowy, D.R. (1982). Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. *Proceedings of the National Academy of Sciences of the United States of America*. 79 (16), pp. 4848-4852.
- Chen, A.Y., Levy, L., Goepfert, H., Brown, B.W., Spitz, M.R. & Vassilopoulou-Sellin, R. (2001). The development of breast carcinoma in women with thyroid carcinoma. *Cancer*. 92 (2), pp. 225-231.
- Chen, R.H., Sarnecki, C. & Blenis, J. (1992). Nuclear localization and regulation of erk- and rsk-encoded protein kinases. *Molecular and cellular biology*. 12 (3), pp. 915-927.
- Cipriani, N.A., Nagar, S., Kaplan, S.P., White, M.G., Antic, T., Sadow, P.M., et al. (2015). Follicular Thyroid Carcinoma: How Have Histologic Diagnoses Changed in the Last Half-Century and What Are the Prognostic Implications? *Thyroid: official journal of the American Thyroid Association*. 25 (11), pp. 1209-1216.
- Cossu, A., Budroni, M., Paliogiannis, P., Palmieri, G., Scognamillo, F., Cesaraccio, R., et al. (2013). Epidemiology of thyroid cancer in an area of epidemic thyroid goiter. *Journal of Cancer Epidemiology*, 2013. pp. 1-4.
- Davies, H. (2002). Mutations of the BRAF gene in human cancer. *Nature*. 417, pp. 949-954.
- Davies, L. & Welch, H.G. (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. *JAMA*. 295 (18), pp. 2164-2167.
- Egan, S.E., Giddings, B.W., Brooks, M.W., Buday, L., Sizeland, A.M. & Weinberg, R.A. (1993). Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. *Nature*. 363 (6424), pp. 45-51.
- Ehrenreiter, K., Kern, F., Velamoor, V., Meissl, K., Galabova-Kovacs, G., Sibilica, M., et al. (2009) Raf-1 addiction in Ras-induced skin carcinogenesis. *Cancer cell*. 16 (2), pp. 149-160.
- Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., et al. (2011). COSMIC: mining

- complete cancer genomes in the Catalogue of Somatic Mutations in Cancer [online]. *Nucleic Acids Research*. 39 (Database issue), pp. D945-D950.
- Franco, C., Martinez, V., Allamand, J.P., Medina, F., Glasinovic, A., Osorio, M., et al. (2009). Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. *Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry*. 17 (3), pp. 211-215.
- Fukahori, M., Yoshida, A., Hayashi, H., Yoshihara, M., Matsukuma, S., Sakuma, Y., et al. (2012). The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. *Thyroid: official journal of the American Thyroid Association*. 22 (7), pp. 683-689.
- Gandara, D.R., Hirt, S., Blumenschein, G.R., Barlesi, F., Delord, J.-P., Madelaine, J., et al. (2013). Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type advanced non-small cell lung cancer: A phase I/Ib trial. *Journal of Clinical Oncology*. 31.
- Gideon, P., John, J., Frech, M., Lautwein, A., Clark, R., Scheffler, J.E., et al. (1992). Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. *Molecular and cellular biology*. 12 (5), pp. 2050-2056.
- Giglione, C., Parrini, M.C., Baouz, S., Bernardi, A. & Parmeggiani, A. (1997). A new function of p120-GTPase-activating protein. Prevention of the guanine nucleotide exchange factor-stimulated nucleotide exchange on the active form of Ha-ras p21. *The Journal of biological chemistry*. 272 (40), pp. 25128-25134.
- Gilles, A., Megléc, E., Pech, N., Ferreira, S., Malausa, T. & Martin, J.-F. (2011). Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. *BMC Genomics*. 12 (1), pp. 1-11.
- Gire, V. & Wynford-Thomas, D. (2000). RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. *Oncogene*. 19 (6), pp. 737-744.
- Goutas, N., Vlachodimitropoulos, D., Bouka, M., Lazaris, A.C., Nasioulas, G. & Gazouli, M. (2008). *BRAF and K-RAS Mutation in a Greek Papillary and*

- Medullary Thyroid Carcinoma Cohort*. 308, pp. 305-308.
- Grimmond, S.M., Raghavan, D. & Russell, P.J. (1992). Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing. *Urological research*. 20 (2), pp. 121-126.
- Grodski, S., Brown, T., Sidhu, S., Gill, A., Robinson, B., Learoyd, D., et al. (2016). Increasing incidence of thyroid cancer is due to increased pathologic detection. *Surgery*. 144 (6), pp. 1038-1043.
- Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B.J., Anderson, D.J., Alvarado, R., et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature*. 464 (7287), pp. 431-435.
- Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., et al. (eds). 2015. SEER Cancer Statistics Review, 1975-2013. National Cancer Institute.
- Huncharek, M. & Muscat, J. (1999). *K- ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases*. 20 (8), pp. 1507-1510.
- Hundahl, S.A., Cady, B., Cunningham, M.P., Mazzaferri, E., McKee, R.F., Rosai, J., et al. (2000). Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. *Cancer*. 89 (1), pp. 202-217.
- Jeong, S.H., Hong, H.S., Kwak, J.J. & Lee, E.H. (2015). Analysis of RAS mutation and PAX8/PPAR $\gamma$  rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings. *Journal of Endocrinological Investigation*. 38 (8), pp. 849-857.
- Johnson, L. (1997). K-ras is an essential gene in the mouse with partial functional overlap with N-ras. *Genes Dev*. 11, pp. 2468-2481.
- Karga, H., Lee, J.-K., Vickery, A.L., Thor, A.N.N., Gaz, R.D. & Jameson, J.L. (1991). Ras Oncogene Mutations in Benign and Malignant Thyroid Neoplasms. *The Journal of Clinical Endocrinology & Metabolism*. 73 (4), pp. 832-836.

- Kilfoy, B., Ward, M.H., Sabra, M.M. & Devesa, S.S. (2011). Thyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992-2006. *Thyroid*. 21 (2), pp. 125-134.
- Kilfoy, B.A., Devesa, S.S., Ward, M.H., Zhang, Y., Rosenberg, P.S., Holford, T.R., et al. (2009a). Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 18 (4), pp. 1092-1100.
- Kilfoy, B.A., Zheng, T., Holford, T.R., Han, X., Ward, M.H., Sjodin, A., et al. (2009b). International patterns and trends in thyroid cancer incidence, 1973-2002. *Cancer causes & control: CCC*. 20 (5), pp. 525-531.
- Knudsen, N., Bulow, I., Laurberg, P., Perrild, H., Ovesen, L. & Jorgensen, T. (2002). Low goitre prevalence among users of oral contraceptives in a population sample of 3712 women. *Clinical endocrinology*. 57 (1), pp. 71-76.
- Ladenson, P., Singer, P., Ain, K. & Al, E. (2000). American Thyroid Association Guidelines for Detection of Thyroid Dysfunction. *Archives of Internal Medicine*. 160 (11), pp. 1573-1575.
- Manenti, G., Pilotti, S., Re, F.C., Della Porta, G. & Pierotti, M.A. (1994). Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. *European journal of cancer (Oxford, England: 1990)*. 30A (7), pp. 987-993.
- Massarelli, E., Varella-Garcia, M., Tang, X., Xavier, A.C., Ozburn, N.C., Liu, D.D., et al. (2007). KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 13 (10), pp. 2890-2896.
- Mazzaferri, E.L. & Jhiang, S.M. (1994). Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *The American journal of medicine*. 97 (5), pp. 418-428.
- McGrath, J.P., Capon, D.J., Smith, D.H., Chen, E.Y., Seeburg, P.H., Goeddel, D. V., et al. (1983). Structure and organization of the human Ki-ras

- proto-oncogene and a related processed pseudogene. *Nature*. 304 (5926), pp. 501-506.
- McTiernan, A., Weiss, N.S. & Daling, J.R. (1987). Incidence of thyroid cancer in women in relation to known or suspected risk factors for breast cancer. *Cancer research*. 47 (1), pp. 292-295.
- Namba, H., Rubin, S.A. & Fagin, J.A. (1990). Point Mutations of Ras Oncogenes are an Early Event in Thyroid Tumorigenesis. *Molecular Endocrinology*. 4 (10), pp. 1474-1479.
- Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R.C., Lee, H., et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature*. 468 (7326), pp. 973-977.
- Nikiforova, M.N., Lynch, R.A., Biddinger, P.W., Alexander, E.K., Dorn, G.W., Tallini, G., et al. (2003). RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. *The Journal of clinical endocrinology and metabolism*. 88 (5), pp. 2318-2326.
- Park, J.Y., Kim, W.Y., Hwang, T.S., Lee, S.S., Kim, H., Han, H.S., et al. (2013a). BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma. *Endocrine pathology*. 24 (2), pp. 69-76.
- Park, S.-J., Sun, J.Y.H., Hong, K., Kwak, J.Y., Kim, E.-K., Chung, W.Y., et al. (2013b). Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. *Clinical chemistry and laboratory medicine*. 51 (8), pp. 1673-1680.
- Peyssonnaud, C. & Eychene, A. (2001). The Raf/MEK/ERK pathway: new concepts of activation. *Biology of the cell / under the auspices of the European Cell Biology Organization*. 93 (1-2), pp. 53-62.
- Prior, I.A., Lewis, P.D. & Mattos, C. (2012). A comprehensive survey of Ras mutations in cancer. *Cancer research*. 72 (10), pp. 2457-2467.
- Pusat Data dan Informasi. (2015a). infoDATIN Pusat Data dan Informasi Kementerian Kesehatan RI: Stop Kanker. *Pusat Data dan Informasi Kementerian Kesehatan RI*.
- Pusat Data dan Informasi. (2015b). Situasi Penyakit Kanker. *Buletin Jendela Data dan Informasi Kesehatan*.
- Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig,

- A.B., Fleshman, J.M. & Matrisian, L.M. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer research*. 74 (11), pp. 2913-2921.
- Rasmussen, N.G., Hornnes, P.J., Hegedus, L. & Feldt-Rasmussen, U. (1989). Serum thyroglobulin during the menstrual cycle, during pregnancy, and post partum. *Acta endocrinologica*. 121 (2), pp. 168-173.
- Rego-Iraeta, A., Perez-Mendez, L.F., Mantinan, B. & Garcia-Mayor, R. V (2009). Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. *Thyroid: official journal of the American Thyroid Association*. 19 (4), pp. 333-340.
- Saika, K., Matsuda, T. & Sobue, T. (2014). Incidence Rate of Thyroid Cancer by Histological Type in Japan. *Japanese Journal of Clinical Oncology* . 44 (11 ), pp. 1131-1132.
- Schulten, H.-J., Salama, S., Al-Ahmadi, A., Al-Mansouri, Z., Mirza, Z., Al-Ghamdi, K., et al. (2013). Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population. *Anticancer research*. 33 (11), pp. 4779-4784.
- Seger, R., Ahn, N.G., Posada, J., Munar, E.S., Jensen, A.M., Cooper, J.A., et al. (1992). Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. *The Journal of biological chemistry*. 267 (20), pp. 14373-14381.
- Sidawy, M.K., Del Vecchio, D.M. & Knoll, S.M. (1997). Fine-needle aspiration of thyroid nodules: correlation between cytology and histology and evaluation of discrepant cases. *Cancer*. 81 (4), pp. 253-259.
- Simard, E.P., Ward, E.M., Siegel, R. & Jemal, A. (2012). Cancers with increasing incidence trends in the United States: 1999 through 2008. *CA: A Cancer Journal for Clinicians*. 62 (2), pp. 118-128.
- Taveras, A.G., Remiszewski, S.W., Doll, R.J., Cesarz, D., Huang, E.C., Kirschmeier, P., et al. (1997). Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. *Bioorganic & medicinal chemistry*. 5 (1), pp. 125-133.

- Tuttle, R.M., Lopez, N., Leboeuf, R., Minkowitz, S.M., Grewal, R., Brokhin, M., et al. (2010). Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. *Thyroid: official journal of the American Thyroid Association*. 20 (3), pp. 257-263.
- Valle, L.A. & Kloos, R.T. (2011). The prevalence of occult medullary thyroid carcinoma at autopsy. *The Journal of clinical endocrinology and metabolism*. 96 (1), pp. E109-E113.
- Vander, J.B., Gaston, E.A. & Dawber, T.R. (1968). The Significance of Nontoxic Thyroid Nodules Final Report of a 15-Year Study of the Incidence of Thyroid Malignancy. *Annals of Internal Medicine*. 69 (3), pp. 537-540.
- Vasko, V., Ferrand, M., Di Cristofaro, J., Carayon, P., Henry, J.F. & de Micco, C. (2003). Specific pattern of RAS oncogene mutations in follicular thyroid tumors. *The Journal of clinical endocrinology and metabolism*. 88 (6), pp. 2745-2752.
- Verkooijen, H.M., Fioretta, G., Pache, J.-C., Franceschi, S., Raymond, L., Schubert, H., et al. (2003). Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. *Cancer Causes & Control*. 14 (1), pp. 13-17.
- Viglietto, G. & De Marco, C. (2011). *Molecular Biology of Thyroid Cancer*. INTECH Open Access Publisher.
- Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., et al. (1988). Genetic Alterations during Colorectal-Tumor Development. *New England Journal of Medicine*. 319 (9), pp. 525-532.
- WHO. (2004). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. pp. 50-52.
- Zhu, X., Zhao, L., Park, J.W., Willingham, M.C. & Cheng, S.-Y. (2014). Synergistic signaling of KRAS and thyroid hormone receptor beta mutants promotes undifferentiated thyroid cancer through MYC up-regulation. *Neoplasia (New York, N.Y.)*. 16 (9), pp. 757-769.
- Zuber, J., Tchernitsa, O.I., Hinzmann, B., Schmitz, A.-C., Grips, M., Hellriegel, M., et al. (2000). A genome-wide survey of RAS transformation targets. *Nat Genet*. 24 (2), pp. 144-152.